X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6909) 6909
Book Review (720) 720
Newsletter (334) 334
Publication (268) 268
Magazine Article (37) 37
Conference Proceeding (22) 22
Book Chapter (10) 10
Trade Publication Article (8) 8
Book / eBook (2) 2
Dissertation (2) 2
Web Resource (2) 2
Data Set (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (5446) 5446
omeprazole (4466) 4466
humans (4000) 4000
pharmacology & pharmacy (3325) 3325
male (3115) 3115
female (2205) 2205
omeprazole - pharmacology (1909) 1909
adult (1877) 1877
proton pump inhibitors (1677) 1677
animals (1668) 1668
middle aged (1532) 1532
gastroenterology & hepatology (1530) 1530
lansoprazole (1218) 1218
2-pyridinylmethylsulfinylbenzimidazoles (1106) 1106
omeprazole - therapeutic use (1097) 1097
rats (1040) 1040
omeprazole - analogs & derivatives (1039) 1039
aged (1010) 1010
anti-ulcer agents - pharmacology (895) 895
anti-ulcer agents - therapeutic use (866) 866
omeprazole - administration & dosage (846) 846
pharmacokinetics (750) 750
helicobacter infections - drug therapy (710) 710
drug interactions (661) 661
helicobacter pylori (617) 617
hydrogen-ion concentration (602) 602
anti-ulcer agents - administration & dosage (574) 574
gastric mucosa - drug effects (566) 566
treatment outcome (561) 561
drug therapy, combination (554) 554
rabeprazole (533) 533
abridged index medicus (508) 508
dose-response relationship, drug (501) 501
ranitidine (499) 499
pantoprazole (491) 491
gastric acid - metabolism (488) 488
omeprazole - pharmacokinetics (478) 478
gastroesophageal reflux - drug therapy (472) 472
proton pump inhibitor (469) 469
enzyme inhibitors - pharmacology (462) 462
adolescent (445) 445
benzimidazoles - pharmacology (445) 445
gastric acid - secretion (443) 443
administration, oral (435) 435
double-blind method (431) 431
therapy (428) 428
helicobacter pylori - drug effects (426) 426
omeprazole - adverse effects (422) 422
cross-over studies (407) 407
pharmacology (394) 394
infection (386) 386
time factors (386) 386
cytochrome p-450 cyp2c19 (383) 383
metabolism (376) 376
drugs (358) 358
medicine & public health (358) 358
esomeprazole (348) 348
rats, sprague-dawley (341) 341
gastric mucosa - metabolism (340) 340
gastroesophageal reflux (335) 335
aged, 80 and over (334) 334
duodenal-ulcer (330) 330
pharmacology/toxicology (325) 325
research (320) 320
proton pump inhibitors - pharmacology (319) 319
amoxicillin (316) 316
eradication (314) 314
area under curve (303) 303
analysis (296) 296
gastrins - blood (296) 296
toxicology (289) 289
anti-bacterial agents - therapeutic use (287) 287
clarithromycin (287) 287
double-blind (285) 285
cytochrome p-450 (279) 279
disease (275) 275
prospective studies (274) 274
proton pump inhibitors - therapeutic use (274) 274
cyp2c19 (271) 271
anti-ulcer agents - adverse effects (267) 267
genotype (267) 267
secretion (267) 267
duodenal ulcer - drug therapy (263) 263
efficacy (263) 263
anti-ulcer agents - pharmacokinetics (262) 262
young adult (260) 260
rats, wistar (258) 258
peptic ulcer - drug therapy (252) 252
gastroesophageal-reflux disease (247) 247
stomach ulcer - drug therapy (247) 247
cytochrome p-450 enzyme system - metabolism (245) 245
drug administration schedule (245) 245
gastric acidity determination (245) 245
amoxicillin - therapeutic use (243) 243
drug therapy (234) 234
h-k (233) 233
risk factors (231) 231
cimetidine (230) 230
mice (230) 230
esophagitis (229) 229
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7009) 7009
Japanese (102) 102
French (49) 49
Spanish (41) 41
German (36) 36
Chinese (18) 18
Russian (16) 16
Italian (10) 10
Ukrainian (8) 8
Portuguese (4) 4
Polish (3) 3
Dutch (2) 2
Hungarian (2) 2
Slovenian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 01/2011, Volume 89, Issue 1, pp. 65 - 74
Four randomized, placebo‐controlled, crossover studies were conducted among 282 healthy subjects to investigate whether an interaction exists between... 
VARIABILITY | LANSOPRAZOLE | RABEPRAZOLE | THERAPY | CARDIOVASCULAR EVENTS | STENT PLACEMENT | PHARMACOLOGY & PHARMACY | OUTCOMES | ANTIPLATELET ACTION | PROTON-PUMP INHIBITORS | DRUG-INTERACTION | Proton Pump Inhibitors - pharmacology | Ticlopidine - pharmacology | Humans | Middle Aged | Half-Life | Male | 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacology | Enzyme Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - blood | Young Adult | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - pharmacology | Adult | Female | Omeprazole - pharmacology | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - pharmacokinetics | Ticlopidine - pharmacokinetics | Enzyme Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Double-Blind Method | Drug Administration Schedule | 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects | Omeprazole - administration & dosage | Enzyme Inhibitors - pharmacology | Omeprazole - adverse effects | Ticlopidine - analogs & derivatives | Cross-Over Studies | Prodrugs - adverse effects | Prodrugs - pharmacokinetics | Cytochrome P-450 CYP2C19 | Platelet Activation - drug effects | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Prodrugs - pharmacology | Ticlopidine - blood | Omeprazole | Pantoprazole | Drug interactions | Analysis | Dosage and administration | Research | Patients | Health aspects | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Drug Metabolism and Disposition, ISSN 0090-9556, 01/2010, Volume 38, Issue 1, pp. 92 - 99
The aim of the current study is to identify the human cytochrome P450 (P450) isoforms involved in the two oxidative steps in the bioactivation of clopidogrel... 
MECHANISM-BASED INHIBITION | ANTIAGGREGATING ACTIVITY | POLYMORPHISMS | TICLOPIDINE | PHARMACOKINETICS | HEALTHY-SUBJECTS | PHARMACOLOGY & PHARMACY | PRASUGREL | PHARMACODYNAMICS | MONOCLONAL-ANTIBODIES | ATORVASTATIN | Microsomes - metabolism | Humans | Aryl Hydrocarbon Hydroxylases - genetics | Cytochrome P-450 Enzyme System - metabolism | Sulfaphenazole - pharmacology | Microsomes - drug effects | Cytochrome P-450 CYP3A - genetics | Cytochrome P-450 CYP1A2 - genetics | Antibodies - immunology | Omeprazole - pharmacology | Microsomes, Liver - enzymology | Platelet Aggregation Inhibitors - pharmacokinetics | Ticlopidine - pharmacokinetics | Oxidoreductases, N-Demethylating - metabolism | Aryl Hydrocarbon Hydroxylases - immunology | Oxidation-Reduction | Enzyme Inhibitors - pharmacology | Ticlopidine - analogs & derivatives | Oxidoreductases, N-Demethylating - immunology | Cytochrome P-450 CYP3A - metabolism | Cell Line, Tumor | Cytochrome P-450 Enzyme System - genetics | Theophylline - pharmacology | Kinetics | Cytochrome P-450 CYP2C9 | Theophylline - analogs & derivatives | Oxidoreductases, N-Demethylating - genetics | Glutathione - metabolism | Ketoconazole - pharmacology | Biotransformation - physiology | Cytochrome P-450 CYP1A2 Inhibitors | Microsomes, Liver - drug effects | Ticlopidine - metabolism | NADP - metabolism | Platelet Aggregation Inhibitors - metabolism | Cytochrome P-450 CYP3A - immunology | Cell Line | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Cytochrome P-450 CYP1A2 - immunology | Biocatalysis | Mephenytoin - analogs & derivatives | Cytochrome P-450 CYP1A2 - metabolism | Aryl Hydrocarbon Hydroxylases - metabolism | Mephenytoin - pharmacology | Antibodies - pharmacology | Cytochrome P-450 CYP3A Inhibitors | Cytochrome P-450 CYP2C19 | Clopidogrel | Cytochrome P-450 CYP2B6 | Index Medicus
Journal Article
Journal Article
Journal of Gastroenterology and Hepatology (Australia), ISSN 0815-9319, 2010, Volume 25, Issue 1, pp. S111 - S118
Journal Article
Investigational New Drugs, ISSN 0167-6997, 4/2018, Volume 36, Issue 2, pp. 248 - 258
Aim Two studies investigated the effect of gastric acid reducing agents and strong inducers/inhibitors of CYP3A4 on the pharmacokinetics of alisertib, an... 
Aurora A kinase | Medicine & Public Health | Alisertib | Induction | Oncology | Drug-drug interactions | Inhibition | Pharmacology/Toxicology | CYP3A4 | SELECTIVE AURORA | ADVANCED SOLID TUMORS | SAFETY | PHASE-II | PHARMACODYNAMICS | ONCOLOGY | MLN8237 | PHARMACOLOGY & PHARMACY | CARCINOMA | Drugs, Investigational - pharmacology | Area Under Curve | Pyrimidines - blood | Humans | Drugs, Investigational - pharmacokinetics | Drugs, Investigational - therapeutic use | Esomeprazole - pharmacology | Male | Aurora Kinase A - antagonists & inhibitors | Itraconazole - pharmacology | Esomeprazole - therapeutic use | Dose-Response Relationship, Drug | Female | Rifampin - therapeutic use | Azepines - blood | Pyrimidines - pharmacology | Azepines - therapeutic use | Azepines - pharmacology | Itraconazole - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - pharmacokinetics | Azepines - pharmacokinetics | Protein Kinase Inhibitors - pharmacology | Rifampin - pharmacology | Complications and side effects | Dosage and administration | Research | Drug therapy | Rifampin | Cancer | Itraconazole | Reducing agents | Pharmacology | Variance analysis | Patients | Omeprazole | Confidence intervals | Studies | Inhibitors | Metabolites | Acids | Pharmacokinetics | Gastric juice | Inducers | Index Medicus | Phase I Studies
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 11/2004, Volume 96, Issue 22, pp. 1702 - 1713
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 01/2018, Volume 84, Issue 1, pp. 112 - 121
AimsThis phase 1, open-label, crossover study sought to evaluate drug-drug interactions between tivantinib and cytochrome P450 (CYP) substrates and tivantinib... 
pharmacokinetics | cancer | P‐glycoprotein | cytochrome P450 | tivantinib | drug interaction | P-glycoprotein | ADVANCED HEPATOCELLULAR-CARCINOMA | TARGETING MET | CYTOTOXIC ACTIVITY | COOPERSTOWN 5+1 COCKTAIL | CELL LUNG-CANCER | TYROSINE KINASE INHIBITORS | METABOLISM | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | MET INHIBITION | PHASE-I | Neoplasms - metabolism | Quinolines - blood | Chromatography, High Pressure Liquid - methods | Humans | Middle Aged | Omeprazole - blood | Cytochrome P-450 Enzyme System - metabolism | Male | Antineoplastic Agents - therapeutic use | Quinolines - pharmacology | Warfarin - pharmacology | Drug Interactions | Neoplasms - blood | Pyrrolidinones - pharmacology | Aged, 80 and over | Caffeine - pharmacology | Adult | Female | Omeprazole - pharmacology | Antineoplastic Agents - pharmacology | Tandem Mass Spectrometry - methods | Proto-Oncogene Proteins c-met - antagonists & inhibitors | Caffeine - blood | Pyrrolidinones - therapeutic use | Pyrrolidinones - blood | ATP Binding Cassette Transporter, Subfamily B - metabolism | Neoplasms - drug therapy | Cross-Over Studies | Drug Therapy, Combination - methods | Midazolam - blood | Warfarin - blood | Antineoplastic Agents - blood | Aged | Quinolines - therapeutic use | Midazolam - pharmacology | Medical research | Care and treatment | Warfarin | Digoxin | Drug interactions | Cytochrome P-450 | Omeprazole | Complications and side effects | Analysis | Medicine, Experimental | Dosage and administration | Tumors | Caffeine | Index Medicus
Journal Article
The AAPS Journal, ISSN 1522-1059, 3/2005, Volume 7, Issue 1, pp. E6 - E13
The DPX-2 cell line, a derivative of HepG2 cells, harbors human PXR and a luciferase-linked CYP3A4 promoter. These cells were used in a panel of cell-based... 
Biotechnology | drug-drug interactions | induction | Pharmacy | DPX-2 cell line | inhibition | Pharmacology/Toxicology | CYP3A4 | Drug-drug interactions | Inhibition | Induction | ACTIVATION | DRUG-INTERACTIONS | REPORTER GENE ASSAY | PREGNANE-X-RECEPTOR | CYTOCHROME-P450 3A4 | DISCOVERY | HUMAN HEPATOCYTES | RELEVANCE | PHARMACOLOGY & PHARMACY | EXPRESSION | Transcription, Genetic - drug effects | Paclitaxel - pharmacology | Cytochrome P-450 Enzyme Inhibitors | Lovastatin - pharmacology | Cytochrome P-450 CYP3A | Humans | Dimethyl Sulfoxide - pharmacology | Neoplasm Proteins - antagonists & inhibitors | Cell Line, Tumor - drug effects | Lovastatin - analogs & derivatives | Ketoconazole - pharmacology | Luciferases - genetics | Recombinant Fusion Proteins - antagonists & inhibitors | Dexamethasone - pharmacology | Chromans - pharmacology | Cytochrome P-450 CYP1A2 - genetics | Enzyme Induction - drug effects | Omeprazole - pharmacology | Phenytoin - pharmacology | Troleandomycin - pharmacology | Liver Neoplasms - enzymology | Neoplasm Proteins - genetics | Thiazolidinediones - pharmacology | Genes, Reporter | Recombinant Fusion Proteins - biosynthesis | Nifedipine - pharmacology | Cell Line, Tumor - enzymology | Neoplasm Proteins - biosynthesis | Clotrimazole - pharmacology | Genes, Synthetic | Receptors, Cytoplasmic and Nuclear - genetics | Carcinoma, Hepatocellular - enzymology | Cytochrome P-450 CYP1A2 - biosynthesis | Enhancer Elements, Genetic | Receptors, Steroid - genetics | Cytochrome P-450 Enzyme System - biosynthesis | Rifampin - pharmacology | Mifepristone - pharmacology | Pregnane X Receptor | Troglitazone | Index Medicus
Journal Article
Clinical Pharmacology in Drug Development, ISSN 2160-763X, 07/2016, Volume 5, Issue 4, pp. 269 - 277
Paritaprevir (administered with low‐dose ritonavir), ombitasvir, and dasabuvir are direct‐acting antiviral agents administered as combination regimens for the... 
hepatitis C virus | omeprazole | drug–drug interaction | CYP2C19 | acid‐reducing agent | Omeprazole | Acid-reducing agent | Drug-drug interaction | Hepatitis C virus | acid-reducing agent | GASTRIC-ACID-SECRETION | ABT-450/R-OMBITASVIR | CHRONIC HEPATITIS-C | RIBAVIRIN | METABOLISM | CYTOCHROME-P450 ENZYMES | TREATMENT-EXPERIENCED PATIENTS | PROTON PUMP INHIBITOR | PHARMACOLOGY & PHARMACY | drug-drug interaction | RITONAVIR | Antiviral Agents - pharmacokinetics | Area Under Curve | Humans | Male | Anilides - pharmacokinetics | Carbamates - administration & dosage | Carbamates - pharmacokinetics | Macrocyclic Compounds - pharmacology | Anti-Ulcer Agents - pharmacokinetics | Uracil - pharmacology | Drug Interactions | Uracil - administration & dosage | Cytochrome P-450 CYP2C19 - drug effects | Adult | Anti-Ulcer Agents - pharmacology | Female | Omeprazole - pharmacology | Ritonavir - pharmacology | Drug Therapy, Combination | Carbamates - pharmacology | Antiviral Agents - pharmacology | Ritonavir - administration & dosage | Omeprazole - administration & dosage | Macrocyclic Compounds - pharmacokinetics | Omeprazole - pharmacokinetics | Sulfonamides - pharmacology | Antiviral Agents - administration & dosage | Sulfonamides - pharmacokinetics | Anti-Ulcer Agents - administration & dosage | Ritonavir - pharmacokinetics | Anilides - administration & dosage | Anilides - pharmacology | Cytochrome P-450 CYP2C19 - metabolism | Macrocyclic Compounds - administration & dosage | Uracil - pharmacokinetics | Sulfonamides - administration & dosage | Uracil - analogs & derivatives | Index Medicus
Journal Article
Molecules, ISSN 1420-3049, 11/2017, Volume 22, Issue 11, p. 1994
Journal Article
The Journal Of Clinical Pharmacology, ISSN 0091-2700, 05/2005, Volume 45, Issue 5, pp. 555 - 563
Dabigatran etexilate is an oral low-molecular-weight direct thrombin inhibitor. Following oral administration, dabigatran etexilate is rapidly converted to its... 
Dabigatran etexilate | Total hip replacement | Pharmacokinetics | Venous thromboembolism | Direct thrombin inhibitor | ENOXAPARIN | SURGERY | dabigatran etexilate | MANAGEMENT | total hip replacement | PREVENTION | DALTEPARIN | direct thrombin inhibitor | KNEE REPLACEMENT | venous thromboembolism | pharmacokinetics | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | II RANDOMIZED-TRIAL | Area Under Curve | Humans | Middle Aged | Thrombin - antagonists & inhibitors | Pyridines - pharmacokinetics | Male | Metabolic Clearance Rate | Dabigatran | Absorption | Drug Interactions | Aged, 80 and over | Adult | Female | Omeprazole - pharmacology | Sulfoxides - pharmacology | Proton Pump Inhibitors | Administration, Oral | Food-Drug Interactions | Benzimidazoles - pharmacokinetics | Arthroplasty, Replacement, Hip | Cross-Over Studies | 2-Pyridinylmethylsulfinylbenzimidazoles | Benzimidazoles - pharmacology | Aged | Omeprazole - analogs & derivatives | Prevention | Evaluation | Thrombophlebitis | Antithrombins | Research | Index Medicus | Thrombin/antagonists & inhibitors | Oral | 80 and over | Surgery | Benzimidazoles/pharmacokinetics/pharmacology | Administration | H(+)-K(+)-Exchanging ATPase/antagonists & inhibitors | Arthroplasty | Replacement | Pyridines/pharmacokinetics | Kirurgi | Hip | Sulfoxides/pharmacology | Omeprazole/analogs & derivatives/pharmacology
Journal Article